Zimmer Biomet Holdings, Inc. (ZBH) Income Statement

The deceleration from 9.3% to 4.8% suggests a normalization after a strong quarter, possibly reflecting lumpy capital equipment sales or procedure volume fluctuations. The underlying trend appears stable, with growth consistently positive over the past year, though not accelerating. Investors should monitor whether this stability persists or if competitive pressures in musculoskeletal devices dampen future growth.

The sequential decline may indicate higher input costs or product mix shifts, but the margin remains structurally high, supported by ZBH's pricing power in reconstructive devices. The 2025Q4 anomaly (64.7%) likely reflects a one-time inventory charge, as margins have since recovered. Compared to peers like SYK (64.0%) and MDT (65.0%), ZBH's gross margin is superior, suggesting a competitive advantage in manufacturing efficiency.

SG&A expenses rose to $899.3M in 2026Q2, up from $849.9M in 2026Q1, while revenue only increased modestly, indicating that operating leverage is not being realized. This may reflect increased selling costs or investments in commercial infrastructure. The operating margin remains below the 19.2% peak in 2024Q4, suggesting that cost discipline is a key area for management to address.

The stable R&D investment suggests a consistent focus on innovation, but the rising SG&A is concerning as it outpaces revenue growth, compressing operating margins. This may indicate increased marketing or administrative costs, which could be a drag on profitability if not managed. Investors should monitor whether SG&A efficiency improves in coming quarters.

This quarter likely included a one-time inventory write-down or restructuring charge, as margins rebounded to 72.1% in 2025Q3 and 70.8% in 2026Q2. The lasting impact is a reminder of the potential for earnings volatility, but the recovery suggests the underlying business is intact. This event may have reset expectations, making future quarters more predictable.